This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Pernix Therapeutics Holdings, Inc.
Drug Names(s): doxepin HCl (low dose)
Pernix, which acquired Somaxon in March 2013, does not report sales for Silenor.
Silenor is a low dose formulation of a drug that is normally used to treat forms of depression/anxiety. In contrast, Silenor is being developed to treat insomnia. It is thought to work by blocking the histamine H1 receptor.
Deal Structure: Silenor was originally developed by Somaxon.
Proctor & Gamble and Somaxon
In August 2010, Somaxon and Proctor & Gamble entered into a co-promotion agreement for Silenor. Somaxon will record all sales of Silenor and will pay Procter & Gamble a combination of fixed fees and a royalty based on U.S. net sales. Each party will be responsible for the costs of maintaining and operating its own sales force, and Somaxon is responsible for all other costs pertaining to the commercialization of Silenor. The term of the agreement runs through December 31, 2012, renewable thereafter, and Somaxon will pay Procter & Gamble a reduced royalty based on U.S. net sales of Silenor for one year after the expiration of the agreement or its earlier termination under certain circumstances.
Paladin and Somaxon
In June 2011, Somaxon and Paladin announced that they entered into an exclusive collaboration under which Paladin will commercialize Silenor (doxepin) for the treatment of...See full deal structure in Biomedtracker
Partners: Procter & Gamble Endo International plc
Additional information available to subscribers only: